Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.
J Gastroenterol Hepatol. 2018 Jan;33(1):277-282. doi: 10.1111/jgh.13819.
Acute liver failure (ALF) is defined as acute liver injury (ALI) associated with coagulopathy. A follow-up strategy for ALI and characterization of ALI patients with a risk of progressing to ALF have never been established. To establish predictive markers for progression from ALI to ALF, this study compared the clinical characteristics and laboratory data on the day of registration to data from a regional referral system of patients with ALI.
This prospective, observational study enrolled 365 consecutive patients with ALI/ALF between 2007 and 2016. We evaluated 109 ALI patients, 27 of whom satisfied the ALF criteria during observation and another 82 patients who recovered without progression to ALF.
Four patients died; all were in the ALF group. The variables of age, incidence of autoimmune hepatitis, model of end-stage liver disease score, values for total bilirubin and prothrombin time (PT)-international ratio, and Japan Hepatic Encephalopathy Prediction Model (JHEPM) probability at registration were significantly higher in ALF patients than in ALI patients. In multivariate analysis, PT and JHEPM were identified as risk factors for progression to ALF. The cut-off values of 13%, 4.9%, 65%, and 1.32% for the model of end-stage liver disease score, JHEPM probability, PT, and PT-international ratio values, respectively, had high negative predictive values. Furthermore, among patients whose JHEPM was underestimated, none died due to ALF.
The JHEPM probability is a predictive parameter that can be used to decide a follow-up treatment strategy for ALI patients.
急性肝衰竭(ALF)定义为伴有凝血障碍的急性肝损伤(ALI)。从未建立过用于 ALI 的随访策略和确定进展为 ALF 风险的 ALI 患者的特征。为了确定从 ALI 进展为 ALF 的预测标志物,本研究比较了登记日的临床特征和实验室数据与区域转诊系统中 ALI 患者的数据。
本前瞻性观察性研究纳入了 2007 年至 2016 年间连续 365 例 ALI/ALF 患者。我们评估了 109 例 ALI 患者,其中 27 例在观察期间符合 ALF 标准,另外 82 例患者无进展为 ALF 而康复。
4 例患者死亡;均在 ALF 组。在 ALF 患者中,年龄、自身免疫性肝炎发生率、终末期肝病模型评分、总胆红素和凝血酶原时间(PT)-国际比值以及登记时日本肝性脑病预测模型(JHEPM)概率等变量显著高于 ALI 患者。多变量分析表明,PT 和 JHEPM 是进展为 ALF 的危险因素。终末期肝病模型评分、JHEPM 概率、PT 和 PT-国际比值的截断值分别为 13%、4.9%、65%和 1.32%,具有较高的阴性预测值。此外,在 JHEPM 被低估的患者中,无一例因 ALF 死亡。
JHEPM 概率是一种预测参数,可用于决定 ALI 患者的随访治疗策略。